Research Reports on DECK, CRM, SPLK, ANAC, GPS

Los Angelas, CA -- (SBWIRE) -- 03/01/2013 -- Deckers Outdoor Corp (NASDAQ:DECK) shares surged 12.97 percent to $45.65. The Company reported Q4 EPS of $2.77, $0.16 better than the analyst estimate of $2.61. Revenue for the quarter came in at $617.3 million versus the consensus estimate of $623.02 million. Deckers Outdoor Corp sees Q1 2013 EPS of ($0.12), versus the consensus of $0.06. The Company currently expects first quarter 2013 revenues to remain flat as compared to first quarter 2012 levels. Based upon current visibility, the Company expects full year revenues to increase approximately 7% over 2012 levels.

Is DECK a Buy After Today’s News? Let’s Find Out Here

Salesforce.com, Inc. (NYSE:CRM) increased 4.98% to $177.65 after market trading hours. The Company reported Q4 EPS of $0.51, $0.11 better than the analyst estimate of $0.40. Revenue for the quarter came rose 32 percent to $835 million versus the consensus estimate of $830.85 million. Salesforce.com, Inc. sees Q1 2014 revenue of $882-887 million, versus the consensus of $886 million - an increase of 27% to 28% year-over-year. The company sees non-GAAP EPS of $0.40 to $0.42, versus the consensus of $0.42. Salesforce.com, Inc. sees FY2014 revenue of $3.82-3.87 billion, versus the consensus of $3.85 billion - an increase of 25% to 27% year-over-year. The company sees Non-GAAP EPS is expected to be in the range of $1.93 to $1.97, versus the consensus of $1.95.

Can CRM Extend Gain? If Yes, How Far It Can Go? Find Out Here

Splunk (NASDAQ:SPLK) is now up 1.83 at $37.96. The Company reported Q4 EPS of $0.03, $0.01 better than the analyst estimate of $0.02. Revenue for the quarter came in at $65.2 million versus the consensus estimate of $60.09 million. Splunk sees Q1 2014 revenue of $52-54 million, versus the consensus of $52 million. Splunk sees FY2014 revenue of $260-270 million, versus the consensus of $263.2 million.

Can SPLK Continue To Move Higher? Find Out Here

Anacor Pharmaceuticals (NASDAQ:ANAC) shares climbed 3.98 percent to $3.63. The Company announced positive preliminary results from the second of two Phase 3 trials of tavaborole (known as Study 302). Tavaborole is a topical anti-fungal for the treatment of onychomycosis, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States. Results from the first Phase 3 trial (known as Study 301) were announced on January 29, 2013. In both studies, tavaborole achieved statistically significant and clinically meaningful results on all primary and secondary endpoints.

Is ANAC Showing Any Sign of Buy At The Current Market Price? Find Out Here

Gap, Inc. (NYSE:GPS) stock rose 2.76 percent to $33.85. The Company reported Q4 EPS of $0.73, $0.02 better than the analyst estimate of $0.71. Revenue for the quarter came in at $4.73 billion versus the consensus estimate of $4.65 billion. The company’s fourth quarter comparable sales were up 5 percent compared with a 4 percent decrease in the fourth quarter last year. Gap, Inc. sees FY2013 EPS of $2.52-$2.60, versus the consensus of $2.59. Also, declared a quarterly dividend of $0.15 per share, or $0.6 annualized. This is a 20% increase from the prior dividend of $0.125.

How Should Investors Trade GPS After The Recent Volatile Moves? Find Out Here

Disclaimer
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com